BioCentury | Jan 29, 2020
Distillery Therapeutics

WWTR1-AXL-ABL2 axis inhibition for brain metastases in lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Blocking a signaling loop comprised of the transcription factor WWTR1 and the tyrosine kinases AXL and ABL2 could treat metastatic lung cancer. AXL and ABL2 signal between each other,...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BioCentury | Nov 7, 2018
Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
BC Week In Review | Jul 13, 2018
Company News

Korean company ABL out-licenses antibody programs to U.S.

ABL Bio Inc. (Seongnam, South Korea) granted Trigr Therapeutics Inc. (Irvine, Calif.) global rights to five of its antibody programs, excluding South Korea. ABL will receive $4.3 million up front and be eligible for $550...
BC Extra | Jul 2, 2018
Company News

Korean company ABL out-licenses antibody programs to U.S.

ABL Bio Inc. (Seongnam, South Korea) granted Trigr Therapeutics Inc. (Irvine, Calif.) global rights to five of its antibody programs, excluding South Korea. ABL will receive $4.3 million up front and be eligible for $550...
BC Week In Review | Jun 15, 2018
Financial News

ABL snags $65M in series C

ABL Bio Inc. (Seongnam, South Korea) raised $65 million on June 8 in a series C round led by new investors DS Asset Management, Alpen Route Asset Management, Quad Asset Management and Hana Financial Investment....
BC Innovations | Nov 10, 2017
Product R&D

Blueprint gets the GIST

Blueprint is positioning its kinase inhibitor BLU-285 to take a dominant position in gastrointestinal tumors, with preclinical and Phase I data showing the compound inhibits not only mutant forms of c-Kit and PDGFRA that underlie...
BC Innovations | Apr 13, 2017
Targets & Mechanisms

Allosteric en-ABL-ement

Novartis AG has developed a new strategy to prevent leukemias from becoming resistant to its CML drugs against BCR-ABL . Rather than combining the inhibitors with other classes of cancer therapies, the company is doubling its...
Items per page:
1 - 8 of 8